MedTrace Logo

Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

NCT02244944 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-02-07

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to gather information on the combination Zetia® (Ezetimibe) and Urso Forte® with respect to sterol balance and their effects on biomarkers of liver function in subjects with nonalcoholic fatty liver disease (NAFLD).

Conditions

  • Nonalcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

EZ-Urso combination therapy

Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day

Sponsors & Collaborators

  • Gregory Graf, PhD

    lead OTHER

Principal Investigators

  • Gregory Graf, PhD · University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02244944 on ClinicalTrials.gov